Compare BIO-TECHNE Corp (TECH) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Tenet Healthcare Corporation — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Tenet Healthcare Corporation trades at $263.78 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and Tenet Healthcare Corporation for 15 Days on average.
| TECH | THC | |
|---|---|---|
Market Cap | $11.36B | $20.98B |
Volume | 5,390,331 | 428,008 |
Sector | Health | Health |
52-Week High | $72.61 | $280.77 |
52-Week Low | $43.31 | $161.37 |
Typical Hold Time | 64 Days | 15 Days |
Enterprise Value | $11.39B | $32.06B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Tenet Healthcare (THC) trades at $260.57, showing modest daily gains of 0.28% with strong technical support at $257 and resistance at $262. The stock demonstrates robust fundamentals with a P/E of 10.07, net income margin of 9.9%, and consistent earnings beats in recent quarters. Recent news highlights the upcoming Q3 2026 earnings release on October 29, 2026, while the company maintains strong cash flow generation of $3.54 billion from operations.
THC presents a compelling investment case with 81% analyst buy ratings and a $283.36 consensus price target representing 8.7% upside potential. The company's expanding capital return strategy and projected revenue growth to $22.6 billion in 2026 support bullish sentiment, though investors should monitor surgical volume trends and capital allocation sustainability as key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
